HK1004219A1 - 3-(5-Tetrazolyl-benzyl)amino-piperidine derivatives and antagonists of tachykinins - Google Patents

3-(5-Tetrazolyl-benzyl)amino-piperidine derivatives and antagonists of tachykinins

Info

Publication number
HK1004219A1
HK1004219A1 HK98103471A HK98103471A HK1004219A1 HK 1004219 A1 HK1004219 A1 HK 1004219A1 HK 98103471 A HK98103471 A HK 98103471A HK 98103471 A HK98103471 A HK 98103471A HK 1004219 A1 HK1004219 A1 HK 1004219A1
Authority
HK
Hong Kong
Prior art keywords
tachykinins
tetrazolyl
antagonists
benzyl
amino
Prior art date
Application number
HK98103471A
Other languages
English (en)
Inventor
Duncan Robert Armour
Brian Evans
Gerard Martin Paul Giblin
Michael Menteith Hann
Tania Hubbard
Xiao-Qing Lewell
David Middlemiss
Alan Naylor
Neil Anthony Pegg
Maria Victoria Vinader
Stephen Paul Watson
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB939319606A external-priority patent/GB9319606D0/en
Priority claimed from GB9326583A external-priority patent/GB9326583D0/en
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Publication of HK1004219A1 publication Critical patent/HK1004219A1/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Otolaryngology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
HK98103471A 1993-09-22 1998-04-24 3-(5-Tetrazolyl-benzyl)amino-piperidine derivatives and antagonists of tachykinins HK1004219A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB939319606A GB9319606D0 (en) 1993-09-22 1993-09-22 Chemical compounds
GB9326583A GB9326583D0 (en) 1993-12-31 1993-12-31 Chemical compounds
PCT/EP1994/003129 WO1995008549A1 (en) 1993-09-22 1994-09-20 3-(5-tetrazolyl-benzyl)amino-piperidine derivatives and antagonists of tachykinins

Publications (1)

Publication Number Publication Date
HK1004219A1 true HK1004219A1 (en) 1998-11-20

Family

ID=26303560

Family Applications (1)

Application Number Title Priority Date Filing Date
HK98103471A HK1004219A1 (en) 1993-09-22 1998-04-24 3-(5-Tetrazolyl-benzyl)amino-piperidine derivatives and antagonists of tachykinins

Country Status (30)

Country Link
US (2) US5703240A (bg)
EP (1) EP0720609B1 (bg)
JP (2) JP2865872B2 (bg)
CN (1) CN1061041C (bg)
AP (1) AP495A (bg)
AT (1) ATE173255T1 (bg)
AU (1) AU681190B2 (bg)
BG (1) BG62169B1 (bg)
CA (1) CA2172529A1 (bg)
CO (1) CO4290298A1 (bg)
CZ (1) CZ285479B6 (bg)
DE (1) DE69414590T2 (bg)
DK (1) DK0720609T3 (bg)
ES (1) ES2123829T3 (bg)
FI (1) FI961270A (bg)
GR (1) GR3029354T3 (bg)
HK (1) HK1004219A1 (bg)
HR (1) HRP940575B1 (bg)
HU (1) HU217428B (bg)
IL (1) IL111002A (bg)
IS (1) IS4208A (bg)
NO (1) NO307830B1 (bg)
NZ (1) NZ273614A (bg)
OA (1) OA10576A (bg)
PE (1) PE18295A1 (bg)
PL (1) PL179585B1 (bg)
SI (1) SI0720609T1 (bg)
SK (1) SK280901B6 (bg)
UA (1) UA44711C2 (bg)
WO (1) WO1995008549A1 (bg)

Families Citing this family (99)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9317987D0 (en) * 1993-08-26 1993-10-13 Glaxo Group Ltd Chemical compounds
IS4208A (is) * 1993-09-22 1995-03-23 Glaxo Group Limited 3-(tetrazólýl-benzyl)amínó-piperadidín afleiður
AU4437896A (en) * 1995-01-12 1996-07-31 Glaxo Group Limited Piperidine derivatives having tachykinin antagonist activity
GB9505692D0 (en) * 1995-03-21 1995-05-10 Glaxo Group Ltd Chemical compounds
GB9513117D0 (en) * 1995-06-28 1995-08-30 Merck Sharp & Dohme Therapeutic agents
TW458774B (en) 1995-10-20 2001-10-11 Pfizer Antiemetic pharmaceutical compositions
US6211199B1 (en) 1995-11-17 2001-04-03 Aventis Pharmaceuticals Inc. Substituted 4-(1H-benzimidazol-2-yl-amino)piperidines useful for the treatment of allergic diseases
GB9525296D0 (en) * 1995-12-11 1996-02-07 Merck Sharp & Dohme Therapeutic agents
US5922737A (en) * 1996-02-21 1999-07-13 Hoechst Marion Roussel, Inc. Substituted N-methyl-N-(4-(4-(1H-Benzimidazol-2-YL-amino) piperidin-1-YL)-2-(arlyl) butyl) benzamides useful for the treatment of allergic diseases
US5998439A (en) 1996-02-21 1999-12-07 Hoescht Marion Roussel, Inc. Substituted N-methyl-N-(4-(piperidin-1-yl)-2-(aryl)butyl)benzamides useful for the treatment of allergic diseases
US5932571A (en) * 1996-02-21 1999-08-03 Hoechst Marion Roussel, Inc. Substituted N-methyl-N-(4-(4-(1H-benzimidazol-2-yl) {1,4}diazepan-1-yl)-2-(aryl) butyl) benzamides useful for the treatment of allergic diseases
JP2000514047A (ja) * 1996-06-26 2000-10-24 ワーナー―ランバート・コンパニー 催吐の処置用医薬の製造のためのタキキニンアンタゴニストの使用
MX9706196A (es) * 1996-08-14 1998-02-28 Pfizer Compuestos triciclicos de piperidinilamino como antagonistas de la sustancia p.
MX9706944A (es) * 1996-09-12 1998-08-30 Pfizer Quinuclidinas sustituidas con tetrazolilo como antagonistas de la sustancia p.
US6117855A (en) 1996-10-07 2000-09-12 Merck Sharp & Dohme Ltd. Use of a NK-1 receptor antagonist and an antidepressant and/or an anti-anxiety agent
DE69732492T2 (de) * 1996-12-02 2006-03-30 Merck Sharp & Dohme Ltd., Hoddesdon Verwendung von nk-1 rezeptorantagonisten zur behandlung von schweren depressionen, die von angstzuständen begleitet werden
AU729708B2 (en) * 1996-12-02 2001-02-08 Merck Sharp & Dohme Limited Use of NK-1 receptor antagonists for treating severe anxiety disorders
WO1998024440A1 (en) * 1996-12-02 1998-06-11 Merck Sharp & Dohme Limited Use of nk-1 receptor antagonists for treating stress disorders
CA2273351A1 (en) * 1996-12-02 1998-06-11 Merck Sharp & Dohme Limited Use of nk-1 receptor antagonists for treating sexual dysfunction
US6613765B1 (en) 1996-12-02 2003-09-02 Merck Sharp & Dohme Limited Use of NK-1 receptor antagonists for treating major depressive disorders
DE69733148T2 (de) * 1996-12-02 2006-02-02 Merck Sharp & Dohme Ltd., Hoddesdon Die verwendung von nk-1 rezeptorantagonisten für die behandlung von kognitiven störungen
WO1998024443A1 (en) * 1996-12-02 1998-06-11 Merck Sharp & Dohme Limited Use of nk-1 receptor antagonists for treating bipolar disorders
US6114315A (en) * 1996-12-02 2000-09-05 Merck Sharp & Dohme Ltd. Use of NK-1 receptor antagonists for treating major depressive disorders with anxiety
AU732633B2 (en) * 1996-12-02 2001-04-26 Merck Sharp & Dohme Limited Use of NK-1 receptor antagonists for treating schizophrenic disorders
CA2273806A1 (en) * 1996-12-02 1998-06-11 Merck Sharp & Dohme Limited Use of nk-1 receptor antagonists for treating substance use disorders
CA2273809A1 (en) * 1996-12-02 1998-06-11 Merck Sharp & Dohme Limited Use of nk-1 receptor antagonists for treating movement disorders
WO1998024438A1 (en) * 1996-12-02 1998-06-11 Merck Sharp & Dohme Limited Use of nk-1 receptor antagonists for treating major depressive disorders
US6100256A (en) * 1996-12-02 2000-08-08 Merck Sharp & Dohme Ltd. Use of NK-1 receptors antagonists for treating schizophrenic disorders
US5977104A (en) * 1996-12-02 1999-11-02 Merck Sharp & Dohme Ltd. Use of NK-1 receptor antagonists for treating bipolar disorders
US5861417A (en) * 1996-12-19 1999-01-19 Hoechst Marion Roussel, Inc. Heterocyclic substituted pyrrolidine amide derivatives
EP0977572A1 (en) * 1997-04-24 2000-02-09 Merck Sharp & Dohme Ltd. Use of nk-1 receptor antagonists for treating eating disorders
JP2002506459A (ja) * 1997-06-27 2002-02-26 メルク シヤープ エンド ドーム リミテツド 置換された３−（ベンジルアミノ）ピペリジン誘導体およびその治療薬としての使用
GB9716463D0 (en) * 1997-08-04 1997-10-08 Merck Sharp & Dohme Therapeutic agents
WO1999007375A1 (en) * 1997-08-04 1999-02-18 Merck Sharp & Dohme Limited Use of nk-1 receptor antagonists for treating aggressive behaviour disorders
GB9716457D0 (en) * 1997-08-04 1997-10-08 Merck Sharp & Dohme Therapeutic agents
CA2298777A1 (en) * 1997-08-04 1999-02-18 Merck Sharp & Dohme Limited Use of nk-1 receptor antagonists for treating mania
GB9723544D0 (en) * 1997-11-07 1998-01-07 Merck Sharp & Dohme Therapeutic agents
US6087348A (en) * 1997-12-01 2000-07-11 Merck Sharp & Dohme Ltd. Use of NK-1 receptor antagonists for treating stress disorders
US6156749A (en) * 1997-12-01 2000-12-05 Merck Sharp & Dohme Limited Use of NK-1 receptor antagonists for treating movement disorders
US6271230B1 (en) 1997-12-01 2001-08-07 Merck Sharp & Dohme Limited Use of NK-1 receptor antagonists for treating cognitive disorders
GB9816897D0 (en) * 1998-08-04 1998-09-30 Merck Sharp & Dohme Therapeutic use
ATE434437T1 (de) * 1999-02-18 2009-07-15 Novasearch Ag Verwendung von antagonisten der 5-ht3-rezeptoren zur behandlung von muskuloeskeletalen erkrankungen
JP2001039954A (ja) * 1999-05-24 2001-02-13 Tomono Agrica Co Ltd ヘテロ環誘導体
AU2001292320A1 (en) * 2000-10-02 2002-04-15 Tanabe Seiyaku Co., Ltd. Benzylamine compound, process for producing the same, and intermediate therefor
AU2002247127A1 (en) 2001-02-14 2002-08-28 Duke University Therapy for cerebral vasospasm
US20040142929A1 (en) * 2001-07-06 2004-07-22 Ramon Merce-Vidal Derivatives of aryl (or heteroaryl) azolylcarbinoles for the treatment of urinary incontinence
US20030083345A1 (en) * 2001-07-10 2003-05-01 Torsten Hoffmann Method of treatment and/or prevention of brain, spinal or nerve injury
US7491737B2 (en) * 2002-10-30 2009-02-17 Merck & Co., Inc. Heterarylpiperidine modulators of chemokine receptor activity
GB0308968D0 (en) * 2003-04-17 2003-05-28 Glaxo Group Ltd Medicaments
CA2531573C (en) * 2003-08-01 2010-04-13 Toyo Kasei Kogyo Company Limited Alkoxy-(tetrazol-1-yl)benzaldehyde compound and process for producing the same
CN1580283A (zh) * 2003-08-13 2005-02-16 清华大学 一种检测核酸分子的方法
DK1689721T3 (da) * 2003-11-26 2010-09-20 Pfizer Prod Inc Aminopyrazolderivater som GSK-3-ihibitorer
GB0409098D0 (en) * 2004-04-23 2004-05-26 Glaxo Group Ltd Medicament
NZ552397A (en) 2004-07-15 2011-04-29 Amr Technology Inc Aryl-and heteroaryl-substituted tetrahydroisoquinolines and use thereof to block reuptake of norepinephrine, dopamine, and serotonin
JP2006137691A (ja) * 2004-11-11 2006-06-01 Toyo Kasei Kogyo Co Ltd ２−アルコキシ−５−テトラゾリル−ベンズアルデヒド化合物の製造方法
WO2006123182A2 (en) 2005-05-17 2006-11-23 Merck Sharp & Dohme Limited Cyclohexyl sulphones for treatment of cancer
KR20080044840A (ko) 2005-07-15 2008-05-21 에이엠알 테크놀로지, 인크. 아릴- 및 헤테로아릴-치환된 테트라히드로벤자제핀, 및노르에피네프린, 도파민 및 세로토닌의 재흡수를 차단하기위한 용도
EP1940842B1 (en) 2005-09-29 2012-05-30 Merck Sharp & Dohme Corp. Acylated spiropiperidine derivatives as melanocortin-4 receptor modulators
GB0603041D0 (en) 2006-02-15 2006-03-29 Angeletti P Ist Richerche Bio Therapeutic compounds
JP5489333B2 (ja) 2006-09-22 2014-05-14 メルク・シャープ・アンド・ドーム・コーポレーション 脂肪酸合成阻害剤を用いた治療の方法
US20110218176A1 (en) 2006-11-01 2011-09-08 Barbara Brooke Jennings-Spring Compounds, methods, and treatments for abnormal signaling pathways for prenatal and postnatal development
PL2336120T3 (pl) 2007-01-10 2014-12-31 Msd Italia Srl Kombinacje zawierające indazole podstawione grupą amidową jako inhibitory polimerazy poli(ADP-rybozy) (PARP)
US8093268B2 (en) 2007-01-24 2012-01-10 Glaxo Group Limited Pharmaceutical compositions comprising 2-methoxy-5-(5-trifluoromethyl-tetrazol-1-yl-benzyl)-(2S-phenylpiperidin-3S-yl-)
EP2145884B1 (en) 2007-04-02 2014-08-06 Msd K.K. Indoledione derivative
CA2963784A1 (en) * 2007-06-08 2008-12-18 Mannkind Corporation Ire-1.alpha. inhibitors
AU2008269154B2 (en) 2007-06-27 2014-06-12 Merck Sharp & Dohme Llc 4-carboxybenzylamino derivatives as histone deacetylase inhibitors
JP2011515343A (ja) 2008-03-03 2011-05-19 タイガー ファーマテック チロシンキナーゼ阻害薬
US9156812B2 (en) 2008-06-04 2015-10-13 Bristol-Myers Squibb Company Crystalline form of 6-[(4S)-2-methyl-4-(2-naphthyl)-1,2,3,4-tetrahydroisoquinolin-7-yl]pyridazin-3-amine
JP2011525538A (ja) * 2008-06-24 2011-09-22 バレアント プハルマセウトイカルス インターナショナル カリウムチャネルモジュレーターとして有用なベンジルオキシアニリド誘導体
US8691825B2 (en) 2009-04-01 2014-04-08 Merck Sharp & Dohme Corp. Inhibitors of AKT activity
WO2010132442A1 (en) 2009-05-12 2010-11-18 Albany Molecular Reserch, Inc. 7-([1,2,4,]triazolo[1,5,-a]pyridin-6-yl)-4-(3,4-dichlorophenyl)-1,2,3,4- tetrahydroisoquinoline and use thereof
EP2429293B1 (en) 2009-05-12 2014-10-29 Bristol-Myers Squibb Company CRYSTALLINE FORMS OF (S)-7-([1,2,4]TRIAZOLO[1,5-a]PYRIDIN-6-YL)-4-(3,4-DICHLOROHPHENYL)-1,2,3,4-TETRAHYDROISOQUINOLINE AND USE THEREOF
EP2429295B1 (en) 2009-05-12 2013-12-25 Albany Molecular Research, Inc. Aryl, heteroaryl, and heterocycle substituted tetrahydroisoquinolines and use thereof
WO2011046771A1 (en) 2009-10-14 2011-04-21 Schering Corporation SUBSTITUTED PIPERIDINES THAT INCREASE p53 ACTIVITY AND THE USES THEREOF
WO2011163330A1 (en) 2010-06-24 2011-12-29 Merck Sharp & Dohme Corp. Novel heterocyclic compounds as erk inhibitors
CA2805265A1 (en) 2010-08-02 2012-02-09 Merck Sharp & Dohme Corp. Rna interference mediated inhibition of catenin (cadherin-associated protein), beta 1 (ctnnb1) gene expression using short interfering nucleic acid (sina)
CA2807307C (en) 2010-08-17 2021-02-09 Merck Sharp & Dohme Corp. Rna interference mediated inhibition of hepatitis b virus (hbv) gene expression using short interfering nucleic acid (sina)
EP2608669B1 (en) 2010-08-23 2016-06-22 Merck Sharp & Dohme Corp. NOVEL PYRAZOLO[1,5-a]PYRIMIDINE DERIVATIVES AS mTOR INHIBITORS
WO2012030685A2 (en) 2010-09-01 2012-03-08 Schering Corporation Indazole derivatives useful as erk inhibitors
EP2615916B1 (en) 2010-09-16 2017-01-04 Merck Sharp & Dohme Corp. Fused pyrazole derivatives as novel erk inhibitors
ES2663009T3 (es) 2010-10-29 2018-04-10 Sirna Therapeutics, Inc. Inhibición de la expresión génica mediada por interferencia por ARN utilizando ácidos nucleicos de interferencia cortos (ANic)
EP2654748B1 (en) 2010-12-21 2016-07-27 Merck Sharp & Dohme Corp. Indazole derivatives useful as erk inhibitors
JP2014514321A (ja) 2011-04-21 2014-06-19 メルク・シャープ・アンド・ドーム・コーポレーション インスリン様増殖因子１受容体阻害剤
ES2672099T3 (es) 2011-07-04 2018-06-12 Irbm - Science Park S.P.A. Antagonistas del receptor NK-1 para el tratamiento de la neovascularización corneal
US9023865B2 (en) 2011-10-27 2015-05-05 Merck Sharp & Dohme Corp. Compounds that are ERK inhibitors
EP3358013B1 (en) 2012-05-02 2020-06-24 Sirna Therapeutics, Inc. Short interfering nucleic acid (sina) compositions
JP6280554B2 (ja) 2012-09-28 2018-02-14 メルク・シャープ・アンド・ドーム・コーポレーションＭｅｒｃｋ Ｓｈａｒｐ ＆ Ｄｏｈｍｅ Ｃｏｒｐ． Ｅｒｋ阻害剤である新規化合物
BR112015012295A8 (pt) 2012-11-28 2023-03-14 Merck Sharp & Dohme Uso de um inibidor de wee1, e, kit para identificar um paciente com câncer
MX2015008196A (es) 2012-12-20 2015-09-16 Merck Sharp & Dohme Imidazopiridinas sustituidas como inhibidores de doble minuto 2 humana.
WO2014120748A1 (en) 2013-01-30 2014-08-07 Merck Sharp & Dohme Corp. 2,6,7,8 substituted purines as hdm2 inhibitors
EP3041938A1 (en) 2013-09-03 2016-07-13 Moderna Therapeutics, Inc. Circular polynucleotides
WO2018071283A1 (en) 2016-10-12 2018-04-19 Merck Sharp & Dohme Corp. Kdm5 inhibitors
EP3645120A4 (en) 2017-06-30 2021-03-24 Chase Pharmaceuticals Corporation NK-1 ANTAGONIST COMPOSITIONS AND METHODS OF USE IN THE TREATMENT OF DEPRESSION
WO2019094311A1 (en) 2017-11-08 2019-05-16 Merck Sharp & Dohme Corp. Prmt5 inhibitors
EP3706747A4 (en) 2017-11-08 2021-08-04 Merck Sharp & Dohme Corp. PRMT5 INHIBITORS
EP3758688B1 (en) 2018-02-26 2024-03-27 Ospedale San Raffaele S.r.l. Nk-1 antagonists for use in the treatment of ocular pain
EP3833668A4 (en) 2018-08-07 2022-05-11 Merck Sharp & Dohme Corp. PRMT5 INHIBITORS
EP3833667B1 (en) 2018-08-07 2024-03-13 Merck Sharp & Dohme LLC Prmt5 inhibitors
US20230134843A1 (en) 2020-03-11 2023-05-04 Ospedale San Raffaele S.R.L. Treatment of stem cell deficiency

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5232929A (en) * 1990-11-28 1993-08-03 Pfizer Inc. 3-aminopiperidine derivatives and related nitrogen containing heterocycles and pharmaceutical compositions and use
UA41251C2 (uk) * 1990-01-04 2001-09-17 Пфайзер, Інк. Гідровані азотвмісні гетероциклічні сполуки, похідні піперидину, фармацевтична композиція та спосіб пригнічення активності речовини р в організмі
US5332817A (en) * 1990-01-04 1994-07-26 Pfizer Inc. 3-aminopiperidine derivatives and related nitrogen containing heterocycles
DK0589924T3 (da) * 1991-06-20 1996-09-30 Pfizer Fluoralkoxybenzylaminoderivater af nitrogenholdige heterocyclusser
WO1994013663A1 (en) * 1992-12-10 1994-06-23 Pfizer Inc. Aminomethylene substituted non-aromatic heterocycles and use as substance p antagonists
IS4208A (is) * 1993-09-22 1995-03-23 Glaxo Group Limited 3-(tetrazólýl-benzyl)amínó-piperadidín afleiður

Also Published As

Publication number Publication date
NO961156D0 (no) 1996-03-21
DK0720609T3 (da) 1999-07-26
NO961156L (no) 1996-05-21
NZ273614A (en) 1997-09-22
FI961270A (fi) 1996-05-03
PL179585B1 (pl) 2000-09-29
BG62169B1 (bg) 1999-04-30
WO1995008549A1 (en) 1995-03-30
SK280901B6 (sk) 2000-09-12
PL313619A1 (en) 1996-07-08
HU9600722D0 (en) 1996-05-28
IS4208A (is) 1995-03-23
JPH09505275A (ja) 1997-05-27
NO307830B1 (no) 2000-06-05
OA10576A (en) 2002-06-03
FI961270A0 (fi) 1996-03-19
PE18295A1 (es) 1995-07-27
HRP940575B1 (en) 2000-06-30
HU217428B (hu) 2000-01-28
AU681190B2 (en) 1997-08-21
AP495A (en) 1996-05-28
CN1061041C (zh) 2001-01-24
EP0720609A1 (en) 1996-07-10
AP9400671A0 (en) 1994-10-31
US5843966A (en) 1998-12-01
ATE173255T1 (de) 1998-11-15
BG100487A (bg) 1996-12-31
IL111002A (en) 1998-09-24
AU7697494A (en) 1995-04-10
GR3029354T3 (en) 1999-05-28
SK38396A3 (en) 1997-02-05
CN1135218A (zh) 1996-11-06
JPH11106341A (ja) 1999-04-20
CZ285479B6 (cs) 1999-08-11
SI0720609T1 (en) 1999-02-28
HRP940575A2 (en) 1997-02-28
CZ83096A3 (en) 1996-09-11
IL111002A0 (en) 1994-11-28
CO4290298A1 (es) 1996-04-17
US5703240A (en) 1997-12-30
ES2123829T3 (es) 1999-01-16
CA2172529A1 (en) 1995-03-30
JP2865872B2 (ja) 1999-03-08
UA44711C2 (uk) 2002-03-15
DE69414590T2 (de) 1999-04-15
HUT75648A (en) 1997-05-28
EP0720609B1 (en) 1998-11-11
DE69414590D1 (de) 1998-12-17

Similar Documents

Publication Publication Date Title
GR3029354T3 (en) 3-(5-tetrazolyl-benzyl)amino-piperidine derivatives and antagonists of tachykinins
IL116917A (en) Piperidine derivatives and pharmaceutical compositions containing them
GR3036881T3 (en) Benzamide derivatives and their use as vasopressin antagonists
IL135800A0 (en) Methods and pharmaceutical compositions for the closure of retinal breaks
ZA944338B (en) Neuropeptide Y Antagonists and Agonists
HU9600813D0 (en) Azole derivatives and pharmaceutical composition thereof
IL111978A0 (en) Dry-compressed paroxetine formulations and their preparation
HUP9900346A3 (en) Endoparasiticidal pharmaceutical compositions containing avermectines and depsipeptides
PL305288A1 (en) Novel piperidine derivatives, method of obtaining them and pharmaceutical agent
IL109782A0 (en) Imidazole-5-position substituted angiotensin II antagonists and pharmaceutical compositions containing them
HU9600589D0 (en) Epibatidine and derivatives thereof as cholinergic receptor agonists and antagonists
IL111379A0 (en) Histamine h3-receptor antagonists and therapeutic uses thereof
ZA943649B (en) Piperidine derivatives their preparation and use
GB9704349D0 (en) Levobupivacaine and its use
HUP9602223A3 (en) Biotin derivatives and pharmaceutical compositions containing them
PL307138A1 (en) Amyline antagonists and agonists
GB9621419D0 (en) 3-3-disubstituted piperidine derivatives and their use as therapeutic agents
GB9704370D0 (en) Levobupivacaine and its use
AU6361494A (en) Anhydroretinol and derivatives thereof as antagonists
HUP9903539A3 (en) Substituted amidinobenzene derivatives and pharmaceutical compositions containing them
GB9722023D0 (en) Levobupivacaine and its use
HUP9602032A2 (en) (thiophen-2-yl)-piperidin or tetrahydropyridin azabiciclocarboxamides and pharmaceutical compositions containing the same
GB9611367D0 (en) Levobupivacaine and its use
PL312100A1 (en) Agent acting highly plasticisingly on and retarding the setting of concrete
SI0923554T1 (en) N-benzylpiperidine and tetrahydropyridine derivatives

Legal Events

Date Code Title Description
PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)